Drug Industry Antitrust Act : hearings before the Antitrust Subcommittee (Subcommittee No. 5) of the Committee on the Judiciary, House of Representatives, Eighty-seventh Congress, second session on H.R. 6245, a bill to amend and supplement the antitrust laws with respect to the manufacture and distribution of drugs and for other purposes, May 17, 18, 23, and 24, 1962.

Committee Serial No. 32. Considers legislation to eliminate anticompetitive practices in the patenting, licensing, and marketing of drugs, and to require FDA standardization of drug names and stricter safety and efficacy standards for new drugs.